Ann: Further Review Shows Major Clinical Benefits from Veyonda, page-5

When the 12-week results for the 1200 mg DARRT cohort were announced on 28 August, there was no mention at all about the 400/800 mg results that had previously been released, and readers had to look through prior announcements to compare both sets of data. This was a serious oversight.

The announcement on 17 September that mentioned the unexpected disclosure by a third party of LuPIN comparison data failed to state the data came from two separate clinical studies involving the same hospital and the same clinicians, as well as similar patient selection criteria and treatment protocols. In other words, it compared apples with apples.

It was a pity that good results were partially obscured by poorly-phrased announcements.

Today's announcement, by comparison, gets straight to the point and lays everything out in an easily understood form, with no need to search for missing information. Graham Kelly is back in town.